Preferred Label : Ibrutinib/Rituximab Regimen;
NCIt synonyms : Ibrutinib/Rituximab; Ibrutinib-Rituximab; Imbruvica/Rituxan;
NCIt related terms : Ibrutinib and Rituximab; Ibrutinib and Rituximab-rite; Ibrutinib and Rituximab-rixi; Ibrutinib and Rituximab-pvvr; Ibrutinib and Rituximab-arrx; Ibrutinib and Rituximab-rixa; Ibrutinib and Rituximab-abbs; Ibrutinib and Rituximab-blit;
NCIt definition : A regimen consisting of ibrutinib and rituximab that may be used in the treatment
of Waldenström macroglobulinemia and certain non-Hodgkin lymphomas (NHL), such as
mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma.;
NCI Metathesaurus CUI : CL969520;
Codes from synonyms : 12543; 127739; 128367; 127896; 128524; 128053; 128681; 128210;
Origin ID : C160529;
UMLS CUI : C5205333;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
https://www.has-sante.fr/jcms/p_3240237/fr/imbruvica-leucemie-lymphoide-chronique-llc
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
ibrutinib
ibrutinib
ibrutinib
guidelines for drug use
leukemia, lymphocytic, chronic, B-Cell
antineoplastic combined chemotherapy protocols
Rituximab
Ibrutinib/Rituximab Regimen
administration, oral
antineoplastic agents
antineoplastic agents
adult
survival analysis
evaluation of the transparency committee
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
---
